What is your preferred treatment option after tarlatamab for patients with ES-SCLC?  

The preferred treatment is a clinical trial - and there are several promising agents in development for SCLC, including a number of antibody-drug conjugates targeting B7-H3, Trop2, SEZ6, and DLL3. Outside of a trial, our treatment algorithms focus on chemotherapy, and my preferred agent here is lurb...

The SCLC treatment paradigm is evolving rapidly from one in which we had few (or sometimes no) options to one in which, if we include experimental options in clinical trials, we are suddenly forced to choose from a surplus of promising agents. For the purposes of this hypothetical question, let us ...